Q2 2019 EPS Estimates for GlaxoSmithKline plc Decreased by Analyst (NYSE:GSK)
GlaxoSmithKline plc (NYSE:GSK) – Investment analysts at Jefferies Financial Group cut their Q2 2019 earnings estimates for shares of GlaxoSmithKline in a research report issued on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford now forecasts that the pharmaceutical company will post earnings per share of $0.64 for the quarter, down from their previous forecast of $0.65. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q3 2019 earnings at $0.82 EPS and FY2023 earnings at $4.05 EPS.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.13. The firm had revenue of $9.98 billion during the quarter, compared to analyst estimates of $9.86 billion. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%.
NYSE:GSK opened at $40.42 on Thursday. GlaxoSmithKline has a 12-month low of $36.41 and a 12-month high of $42.32. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72. The stock has a market capitalization of $100.81 billion, a price-to-earnings ratio of 12.79, a PEG ratio of 2.14 and a beta of 0.74. The company has a fifty day moving average of $40.07.
The firm also recently declared a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were paid a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a yield of 4.90%. The ex-dividend date was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is presently 58.86%.
In other GlaxoSmithKline news, Director Plc Glaxosmithkline purchased 385,714 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $5,399,996.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders acquired 1,044,047 shares of company stock worth $16,249,991. 10.00% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of GSK. Norges Bank acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth about $17,275,000. Two Sigma Investments LP acquired a new stake in shares of GlaxoSmithKline during the fourth quarter worth about $15,936,000. Deutsche Bank AG increased its position in shares of GlaxoSmithKline by 221.0% during the fourth quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock worth $20,222,000 after purchasing an additional 364,431 shares in the last quarter. Millennium Management LLC increased its position in shares of GlaxoSmithKline by 612.0% during the fourth quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock worth $13,959,000 after purchasing an additional 314,016 shares in the last quarter. Finally, Foundry Partners LLC acquired a new stake in shares of GlaxoSmithKline during the first quarter worth about $6,917,000. Institutional investors and hedge funds own 11.26% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Why Dividend Stocks May Be Right for You
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.